Lisata Therapeutics, Inc. (NASDAQ:LSTA – Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 54,600 shares, an increase of 10.5% from the October 15th total of 49,400 shares. Currently, 0.8% of the company’s shares are sold short. Based on an average daily trading volume, of 21,300 shares, the short-interest ratio is presently 2.6 days.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP acquired a new position in Lisata Therapeutics in the 3rd quarter valued at $57,000. State Street Corp acquired a new position in Lisata Therapeutics in the 3rd quarter valued at $66,000. Citadel Advisors LLC bought a new stake in shares of Lisata Therapeutics during the 2nd quarter valued at $64,000. BlackRock Inc. bought a new stake in shares of Lisata Therapeutics during the 3rd quarter valued at $263,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Lisata Therapeutics during the 3rd quarter valued at $467,000. 8.36% of the stock is owned by institutional investors and hedge funds.
Lisata Therapeutics Stock Performance
NASDAQ LSTA opened at $2.24 on Thursday. The stock has a market capitalization of $18.23 million, a price-to-earnings ratio of -0.84 and a beta of 1.16. The stock’s 50 day moving average price is $2.12 and its two-hundred day moving average price is $2.96. Lisata Therapeutics has a 52 week low of $1.95 and a 52 week high of $4.53.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Lisata Therapeutics in a report on Tuesday, August 15th.
Lisata Therapeutics Company Profile
Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; HONEDRA, a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201, a CD34+ cell therapy for the treatment of chronic kidney disease.
- Five stocks we like better than Lisata Therapeutics
- Stock Market Upgrades: What Are They?
- Buffett’s latest portfolio additions, trims, and cuts in Q3
- What is the Hang Seng index?
- 5 reasons TJX Companies will hit new highs in 2024
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Game-changing news for Ambarella puts the market in reversal
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.